TheraVet Announces 300% Increase in Participating Centers in the Osteosarcoma Program Since Its Initiation 6 Months Ago
June 15 2023 - 1:30AM
Business Wire
- Fast-growing interest in Osteosarcoma Program since official
launch end- March 2023 with a 33% increase in participating
Centers
- 16 participating Centers in 7 countries
- Successful participation to the congress of the European
Society of Veterinary Oncology
Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering
company in the management of osteoarticular diseases in pets,
updates on the Osteosarcoma Program and on its participation at
ESVONC (European Society of Veterinary Oncology) congress.
With ~40,000 cases per year in Europe and the United-States,
osteosarcoma is a high added value indication. Indeed, osteosarcoma
is a severe disease with a poor prognosis severely impacting the
quality of life of the patient due to severe pain & decreased
mobility. To date, the only surgical options to locally control the
disease are (i) to remove the affected limb (amputation) which is
not feasible in all patients and also refused by the owners or (ii)
to remove a part of the limb affected to spare the limb
(limb-sparing) using very invasive surgical procedures associated
to high complications rate (up to 80%). Therefore, alternative
solutions are needed to answer to this medical need and overcome
the limitations associated to its actual surgical management.
Being the only minimally invasive limb-sparing solution
(cementoplasty) available, BIOCERA-VET OSTEOSARCOMA RTU is well
positioned as the alternative to amputation for canine
osteosarcoma. Its unique properties (high injectability, long
workability & high mechanical strength) make BIOCERA-VET
OSTEOSARCOMA RTU the tailored product for all intra-osseous
administration procedures (such as cementoplasty). It can also be
combined to all non-surgical management options already available
(such as chemotherapy, radiotherapy or microwave ablation).
In order to make this alternative known, TheraVet’s Osteosarcoma
Program has been officially announced and launched on 30 March 2023
through the dedicated webpage www.bonecancer.dog with the first
objective to gather, around BIOCERA-VET OSTEOSARCOMA RTU and
cementoplasty, a network of user KoLs and clinics and second to
inform pet owners on the disease and on the cementoplasty. Since
the initiation of the program end 2022, the number of
participating centers increased by 300% reaching 16 in 7
countries, and since its official launch 2 months ago, this
number increased by 33%. Also, web traffic and the number of web
users on the www.bonecancer.dog page has been multiplied by
3 over the last month, a sign of a real interest and need about
information for the owners.
Finally, TheraVet was attending the ESVONC, the main European
conference dedicated to veterinary oncology, in Alicante (Spain)
from the 25th to the 27th of May. The Company poster presentation
on the use of minimally invasive calcium phosphate bone substitute
injection for conservative surgical management of appendicular
osteosarcoma was well received by the attending oncologists and
generated great interest. At TheraVet commercial booth, the visits
and contacts targets were largely exceeded, with ~30% of the
conference audience visiting the booth and discussing the
product and cementoplasty.
About TheraVet SA
TheraVet is a veterinary biotechnology company specializing in
osteoarticular treatments for companion animals. The Company
develops targeted, safe and effective treatments to improve the
quality of life of pets suffering from joint and bone diseases. For
pet owners, the health of their pets is a major concern and
TheraVet’s mission is to address the need for innovative and
curative treatments. TheraVet works closely with international
opinion leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris and Brussels, has its head office
in Belgium (Gosselies) with a US subsidiary.
For more information, visit the TheraVet website or follow us on
LinkedIn / Facebook / Twitter
About BIOCERA-VET
In close collaboration with an international scientific board,
THERAVET® has developed a new line of calcium-phosphate and
biological bone substitutes, BIOCERA-VET®. BIOCERA-VET® is a full
range of innovative, easy-to-use, efficient & cost-effective
bone substitutes indicated in bone surgeries where a bone graft is
required and as a palliative alternative in the management of
canine osteosarcoma. Based on extremely promising clinical results,
this line offers the possibility of a better, more convenient and
more efficient orthopedic surgery.
BIOCERA-VET® is declined in different lines:
- BIOCERA-VET® BONE SURGERY RTU, a ready-to-use highly injectable
self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone
graft
- BIOCERA-VET® GRANULES, an affordable biocompatible
calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable
calcium-phosphate bone substitute for cementoplasty
- BIOCERA-VET® COMBO-CLEAN, a local and long-lasting antibiotic
delivery calcium-phosphate bone substitute
For more information, visit BIOCERA-VET website.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230614197649/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
Chief Corporate Officer Julie Winand investors@thera.vet
NewCap Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33 (0)1
44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@newcap.fr Tel: + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
From Jul 2024 to Aug 2024
TheraVet (EU:ALVET)
Historical Stock Chart
From Aug 2023 to Aug 2024